TCM
Tang Capital Management Portfolio holdings
AUM
$1.98B
1-Year Return
21.62%
This Quarter Return
-3.24%
1 Year Return
+21.62%
3 Year Return
+290.69%
5 Year Return
+284.46%
10 Year Return
+928.34%
AUM
$709M
AUM Growth
+$29.4M
(+4.3%)
Cap. Flow
+$74.6M
Cap. Flow
% of AUM
10.53%
Top 10 Holdings %
Top 10 Hldgs %
39.27%
Holding
116
New
17
Increased
23
Reduced
16
Closed
10
Top Buys
| 1 |
EQRX
EQRx, Inc. Common Stock
EQRX
|
$22.4M |
| 2 |
Intellia Therapeutics
NTLA
|
$12.6M |
| 3 |
AVDL
Avadel Pharmaceuticals
AVDL
|
$10.3M |
| 4 |
KalVista Pharmaceuticals
KALV
|
$7.6M |
| 5 |
Tarsus Pharmaceuticals
TARS
|
$6.42M |
Top Sells
| 1 |
BLUE
bluebird bio
BLUE
|
$9.42M |
| 2 |
Capital One
COF
|
$8.75M |
| 3 |
BioCryst Pharmaceuticals
BCRX
|
$4.6M |
| 4 |
Pyxis Oncology
PYXS
|
$4.58M |
| 5 |
Phathom Pharmaceuticals
PHAT
|
$3.58M |
Sector Composition
| 1 | Healthcare | 94.04% |
| 2 | Financials | 5.11% |
| 3 | Real Estate | 0.78% |
| 4 | Consumer Discretionary | 0.07% |
| 5 | Utilities | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Bio-Rad Laboratories Class A
BIO
$7.72B
| $8.6M | 1.21% |
24,000
+8,000
| +50% | +$2.87M |
|
27
InflaRx
IFRX
$108M
| $8.42M | 1.19% |
2,824,353
-75,647
| -3% | -$225K |
|
28
CytomX Therapeutics
CTMX
$340M
| $8.32M | 1.17% |
6,450,000
-150,000
| -2% | -$194K |
|
29
Dianthus Therapeutics
DNTH
$783M
| $8.09M | 1.14% |
591,636
+212,886
| +56% | +$2.91M |
|
30
NovoCure
NVCR
$1.31B
| $7.95M | 1.12% |
492,100
+392,100
| +392% | +$6.33M |
|
31
Moderna
MRNA
$9.23B
| $7.92M | 1.12% |
76,700
| – | – |
|
|
MRTX
32
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $7.84M | 1.11% |
180,000
+100,000
| +125% | +$4.36M |
|
33
Verastem
VSTM
$607M
| $7.25M | 1.02% |
891,514
-248,486
| -22% | -$2.02M |
|
34
Altimmune
ALT
$315M
| $7.15M | 1.01% |
2,750,000
| – | – |
|
35
Zymeworks
ZYME
$1.08B
| $6.97M | 0.98% |
1,100,000
| – | – |
|
36
BioAtla
BCAB
$28.2M
| $6.42M | 0.91% |
3,778,393
+104,317
| +3% | +$177K |
|
37
uniQure
QURE
$918M
| $6.28M | 0.89% |
+935,800
| New | +$6.28M |
|
38
Aurinia Pharmaceuticals
AUPH
$1.59B
| $5.83M | 0.82% |
750,000
+600,000
| +400% | +$4.66M |
|
39
Cullinan Oncology
CGEM
$396M
| $5.62M | 0.79% |
621,138
+171,138
| +38% | +$1.55M |
|
|
EQC
40
DELISTED
Equity Commonwealth
EQC
| $5.51M | 0.78% |
300,000
+200,000
| +200% | +$3.67M |
|
|
TECX
41
Tectonic Therapeutic, Inc. Common Stock
TECX
$340M
| $5.41M | 0.76% |
292,724
+67,307
| +30% | +$1.24M |
|
|
AMRN
42
Amarin Corp
AMRN
$307M
| $5.39M | 0.76% |
293,126
-61,874
| -17% | -$1.14M |
|
|
LENZ
43
LENZ Therapeutics
LENZ
$1.12B
| $5M | 0.71% |
288,089
-9,857
| -3% | -$171K |
|
44
ADMA Biologics
ADMA
$3.98B
| $4.87M | 0.69% |
1,360,000
+100,000
| +8% | +$358K |
|
45
Dynavax Technologies
DVAX
$1.19B
| $4.43M | 0.63% |
300,000
| – | – |
|
46
Insmed
INSM
$30B
| $4.2M | 0.59% |
166,203
| – | – |
|
47
Citigroup
C
$177B
| $4.11M | 0.58% |
100,000
| – | – |
|
|
ADAP
48
Adaptimmune Therapeutics
ADAP
$12.9M
| $4.03M | 0.57% |
5,166,954
+279,716
| +6% | +$218K |
|
49
Quince Therapeutics
QNCX
$85.9M
| $3.92M | 0.55% |
3,498,868
-114,412
| -3% | -$128K |
|
50
Veritex Holdings
VBTX
$1.89B
| $3.77M | 0.53% |
210,000
| – | – |
|